MDM2 and hepatocellular carcinoma: In a recent study on an experimental mouse liver cancer model, diosmin decreased the growth of HA22T cells in human hepatocellular cancer by downregulating the PI3K–Akt–MDM2 signaling pathway and triggering G2/M cell cycle arrest (Dung et al., 2012).